Shortly after World War II, when penicillin and other antimicrobial agents became available for clinical use, children with serious infection responded dramatically to these "miracle drugs." Indeed, we anticipated that children soon would be spared the consequences of bacterial infections. It was noted, however, that on rare occasion, children responded slowly to the appropriate antimicrobial therapy and suffered recurrent pneumonia and abscesses of the liver, bones, or lungs.

Dr. Charles Janeway described the clinical course of several such children in 1954 at a national pediatric meeting \[[@CIT0001]\]. His presentation prompted responses from pediatric infectious diseases specialists in several US cities who described children with similar disappointing responses to antibiotics, recurrent serious infections, and early death.

Dr. Robert Good and his coworkers at the University of Minnesota investigated several of these children and found hyperimmune responses to infecting bacteria---high levels of gamma globulin overall and of specific antibodies to infecting bacterial antigens. All of the children they studied died before 10 years of age. "A Fatal Granulomatous Disease of Childhood" was the title of the first report that described these children \[[@CIT0002]\].

In 1967, I developed a method for measuring the kinetics of engulfment and intracellular killing of bacteria by human peripheral blood polymorphonuclear leukocytes (neutrophils) and used it in my laboratory at the University of Minnesota to study children with a presumptive diagnosis of fatal granulomatous disease \[[@CIT0003]\]. The patients' neutrophils engulfed *Staphylococcus aureus* and other bacteria normally; however, the intracellular bacteria were not killed. In contrast, normal human neutrophils killed the bacteria instantly.

It is difficult to convey the excitement and optimism in our laboratory when we realized that these children were "nature's own experiments" and could provide identification of the bactericidal power of normal human neutrophils.

The neutrophils of the mothers of these children exhibited intermediate kinetics of intracellular killing of bacteria, which revealed the syndrome to be an X-linked genetic defect of phagocytic cells. The defect in phagocytic cells from these patients was proven to affect the oxidative response during phagocytosis. A remarkable difference occurred in the clinical course of children with this syndrome (now known as chronic granulomatous disease) \[[@CIT0003]\]. Antibiotics were used in higher doses and more aggressively (ie, intravenously). Continuous prophylaxis with antibacterial and antifungal agents became standard therapy.

I believe that the understanding by patients and their families that the cells involved in their host defense against bacteria are compromised prompted compulsive adherence to recommendations about personal hygiene and acceptance of prompt surgical attention when necessary. The patients with chronic granulomatous disease became partners in their own medical care, and indeed, several of them and their families were guests at a University of Minnesota celebration of my 70th birthday in 1995.
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